Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03004209|
Recruitment Status : Unknown
Verified December 2016 by Kon Chu, Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : December 28, 2016
Last Update Posted : December 29, 2016
|Condition or disease||Intervention/treatment||Phase|
|Autoimmune Encephalitis||Drug: Erythropoietin||Phase 4|
Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production.
We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2017|
Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
three times per a week 100IU / k
Other Name: Epokine prefilled injection
- Change from Baseline modified Rankin Scale (mRS) at 12th week [ Time Frame: 2nd week, 12th week ]Favorable outcome is an improvement of mRS score.
- Adverse effect [ Time Frame: 2nd week, 4th week, 8th week, 12th week ]Common terminology criteria for adverse events (CTCAE) 4.0
- Quality of Life in Epilepsy Inventory (QOLIE) -31 [ Time Frame: 2nd week, 4th week, 8th week, 12th week ]
- Mini-Mental State Examination (MMSE) [ Time Frame: 2nd week, 4th week, 8th week, 12th week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004209
|Contact: Keun Tae Kim, M.Semail@example.com|
|Korea, Republic of|
|Seoul National University Hospital||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Kon Chu, Ph.D firstname.lastname@example.org|
|Contact: Keun Tae Kim, M.S. email@example.com|
|Principal Investigator: Kon Chu, MD, PhD.|
|Principal Investigator:||Kon Chu, Ph.D||Seoul National University Hospital|